ACE2 Pathway Stimulation Enhances VEGF Inhibition in ccRCC, May Help Overcome VEGF Resistance
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
Genitourinary Cancers Symposium
Bladder Pressure May Influence Intravesical Drug Delivery
Using porcine bladders, researchers investigated whether bladder pressure affects the extent to which gemcitabine penetrates the bladder wall with this treatment modality.
Olaparib Has Limited Antitumor Activity Against Some HRR Genes in mCRPC
Olaparib had greater antitumor activity against BRCA1/2-mutant metastatic castration-resistant prostate cancer (mCRPC).
Primary EV-301 Results Confirm Enfortumab Vedotin’s Superiority Over Chemotherapy in Advanced Urothelial Carcinoma
Powles et al present the primary results from the phase 3 EV-301 trial in advanced urothelial carcinoma.
Nivolumab, Docetaxel, and ADT Triplet Confers Antitumor Activity in mCRPC Regardless of Prior NAT Use
Karim Fizazi, MD, PhD, presents final analysis results from arm B of the phase 2 CheckMate 9KD trial.
Real-World Data: Cabozantinib Used More Commonly Than Other TKIs After Checkpoint Inhibition in mRCC
Investigators of this retrospective observational cohort study evaluated outcomes with cabozantinib or other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma (RCC) following immune checkpoint inhibition.
Final TITAN Analysis Confirms Superior OS Benefit With Apalutamide and ADT Versus ADT Alone
The final analysis of the phase 3 TITAN trial included nearly 4 years of follow-up.
Adjuvant Nivolumab Improves DFS in MIUC After Radical Surgery
CheckMate 274 investigators compared adjuvant nivolumab with placebo (PBO) in patients with MIUC who received cisplatin prior to radical surgery.
No Association Between ADT and SARS-CoV-2 Infection in Prostate Cancer
The aim of this study was to determine whether androgen deprivation therapy (ADT) affords protection against SARS-CoV-2 infection in a population of patients with prostate cancer.
Survival Trends Analysis Shows Significant OS Gains for MIBC, But Not Urothelial Carcinoma
Investigators of this real-world analysis studied survival trends among patients with muscle-invasive bladder cancer (MIBC) and patients with metastatic urothelial carcinoma (UC).
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Genitourinary Cancers Symposium
Loading... 
Loading...